

Center for Vaccine  
Ethics and Policy



**Vaccines and Global Health: The Week in Review**  
**17 February 2024 :: Issue 738**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

## ***Milestones, Perspectives***

.....  
.....

### **Cholera – Grade 3 Emergency**

#### **[Multi-country outbreak of cholera, External situation report #11](#)**

12 February 2024

##### *Overview*

**The persistence of cholera is evident as 2024 begins, with 40 900 cases and 775 deaths reported in January alone from 17 countries across four regions:** the African Region, the Eastern Mediterranean Region, the Region of the Americas, and the South-East Asia Region. Zambia and Zimbabwe have experienced the highest surges, underscoring the ongoing challenge of controlling cholera and the importance of sustained public health efforts. In 2023, cases were reported in 30 countries across five WHO regions, including nine countries that recorded more than 10 000 cases.

**The global cholera response continues to be affected by a critical shortage of Oral Cholera Vaccines (OCV). From January 2023 to January 2024, urgent requests for OCV surged, with 76 million OCV doses requested by 14 countries while only 38 million doses were available during that time period.** The global stockpile of vaccines is awaiting replenishment and all production up to 8 March will be allocated to requests already approved.

**WHO classified the global resurgence of cholera as a grade 3 emergency in January 2023,** its highest internal level for emergencies. Based on the number of outbreaks and their geographic expansion, alongside the shortage of vaccines and other resources, WHO continues to assess the risk at global level as very high and the event remains classified as a grade 3 emergency.

PDF: [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20240212\\_multi-country\\_outbreak-of-cholera\\_sitrep\\_11.pdf?sfvrsn=6a8a6b28\\_3&download=true](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20240212_multi-country_outbreak-of-cholera_sitrep_11.pdf?sfvrsn=6a8a6b28_3&download=true)

*[Excerpts]*

p.13

#### **Vaccination**

- **Three new requests were received in 2024 from Ethiopia, Somalia, and Zambia, collectively seeking over six million doses. Additionally, two other countries (Burundi and Yemen) are considering submitting an OCV request for a reactive campaign.. However, the global OCV stockpile is currently depleted, with no doses available until beginning of March. Four requests awaiting production release for shipment to affected countries. This shortage presents a significant challenge to cholera response efforts.**
- Since the onset of 2024, four reactive vaccination campaigns have been conducted in response to cholera outbreaks in four countries: Ethiopia, Mozambique, Zambia, and Zimbabwe. These campaigns are critical in curtailing the spread of the disease. However, given the current context of outbreaks and limited vaccine availability, only single-dose vaccination courses have been validated and utilized in these reactive campaigns.
- Moreover, the constrained supply of OCVs is severely impacting the capacity to carry out preventive vaccination campaigns. The limited global stockpile of OCVs underscores the need for increased

production and strategic stockpile management to ensure that both reactive and preventive needs are adequately met.

p. 16

### **Key challenges**

The geographical spread and global surge in cases is due to and has resulted in numerous challenges:

- Exacerbation of cholera outbreaks due to natural disasters and climatic effects.
- Data quality and reporting, including issues with reporting consistency and insufficient disaggregation of data for vulnerable groups, especially for children under 5 years of age. Insufficient OCV stocks to respond to all concurrent cholera outbreaks, resulting in the suspension of preventive campaigns and a transition from a two-dose to a one-dose strategy. In January 2024, the vaccine stockpile was entirely depleted.
- Exhausted national cholera response capacities and overall overstretched emergency response capacity due to numerous parallel large-scale and high-risk outbreaks and other emergencies affecting public health.
- Limited experienced cholera response staff available for deployments to support national emergency responses.
- Inadequate financial resources to respond in a timely and effective manner across all levels.
- A lack of resources, both financial and material, for prevention, readiness, and preparedness activities.

### **Next steps**

To address the challenges identified above, WHO, UNICEF and partners will continue to work together.

- Cholera scenario planning/prioritization will continue to be updated, considering the potential impact of a severe El Niño event at the global, regional, and national levels.
- WHO will continue to advocate for investment in cholera response, highlighting that long-term investment is critical for a sustainable solution, while emphasizing that immediate investment is needed for rapid emergency response to the current surge in cases.
- **WHO and UNICEF will continue to work with partners to streamline the supply for essential cholera materials, including vaccines, ensuring maximum availability based on the prioritization of needs.**
- WHO and partners, including the GTFCC, will continue to support Ministries of Health and implementing partners with the latest available information and material to enable prevention and response activities in the current constrained environment.
- WHO, UNICEF, and partners will continue to work together to maintain focus on the cholera emergency, to mobilize resources and lobby for long term solutions to reduce the cholera burden. In addition, WHO, UNICEF and other partners will continue to work together to streamline response efforts and maximize limited resources.

.....

.....

## **[Emergency response framework \(ERF\), Edition 2.1 – Internal WHO Procedures](#)**

12 February 2024

### *Overview*

**The ERF provides WHO staff with essential guidance on how the Organization manages the assessment, grading and response to public health events and emergencies with health consequences**, in support of Member States and affected communities. The ERF adopts an all-hazards approach and it is therefore applicable in all acute public health events and emergencies.

This version (2024) of the WHO ERF has been developed following extensive consultation across the three levels of the Organization and response experiences over the last five years of emergency

response. **Key areas have been updated to improve the accountability, predictability, timeliness and effectiveness of WHO's response to emergencies.**

PDF: <https://iris.who.int/bitstream/handle/10665/375964/9789240058064-eng.pdf?sequence=1>

### *Executive summary*

World Health Organization (WHO) Member States face increasing numbers of emergencies with health consequences from all hazards, including biological hazards (e.g. epidemics and pandemics), societal hazards (e.g. armed conflicts, civil unrest), meteorological and hydrological hazards, geohazards (e.g. earthquakes), environmental hazards, chemical hazards, extraterrestrial hazards, and technological hazards. Emergencies can be complex, with more than one cause, and can have significant public health, social, economic and political impacts.

**WHO has specific responsibilities and accountabilities for health emergency operations under the International Health Regulations (2005) (IHR) and the Inter-Agency Standing Committee (IASC), and as mandated in the WHO Thirteenth General Programme of Work 2019–2023.**<sup>1</sup> Further efforts are underway to strengthen the global architecture for health emergency preparedness, prevention, response and resilience (HEPR), at the national and international levels.<sup>2</sup>

This work is under development and will focus on global governance, financing and emergency preparedness and response systems. During this process, WHO's support to Member States will continue although the modality of delivery and responsibilities may evolve in line with the adoption and implementation of the HEPR architecture.

WHO's responsibilities begin with early detection, verification and risk assessment of an event (Chapter 1). Events that require a public health response by WHO which exceeds the usual country-level cooperation of the country office with the Member State are referred for grading to determine the level of WHO's operational response (Chapter 2). WHO's operational response to emergencies is managed through the incident management system (IMS) (Chapter 3), which is based on recognized best practices of emergency management and used by emergency responders globally, including within the health sector. Performance standards and emergency procedures are described in Chapter 4 and Chapter 5, respectively.

### *Update from prior version*

This update aims to further improve the predictability, timeliness and effectiveness of WHO's response to public health emergencies. It has been developed following consultation across the three levels of the Organization.

This revision updates and expands the concepts within the Emergency Response Framework (ERF) based on lessons learned in recent emergencies about effectively scaling up WHO response to acute public health events. Notable changes include the clarification of accountabilities in an emergency response; clarification of grading levels; and updated descriptions of the functions of the incident management system. Considerations have been added for mainstreaming protection from sexual exploitation, abuse and harassment in emergency operations; operational risk management; management of vaccine-preventable outbreaks; and protracted emergencies. There is also a checklist to aid use of the Contingency Fund for Emergencies (CFE). Performance standards, and associated indicators have been updated accordingly, as have the Organization's emergency response procedures. These updates will be reflected appropriately in the standard operating procedures (SOPs) for emergencies.

1. WHO's Thirteenth General Programme of Work. (<https://www.who.int/about/general-programme-of-work/thirteenth>).
2. Strengthening the global architecture for health emergency prevention, preparedness, response and resilience. (<https://www.who.int/publications/m/item/strengthening-the-global-architecture-for-health-emergency-prevention--preparedness--response-and-resilience>).

# WHO grading of public health events and emergencies

Grading is an internal WHO activation procedure and is not dependent on consultation with Member States or official requests for assistance. The grade indicates the level of operational response required by WHO for that event, not its assessed level of risk.

## Purpose of grading

Grading is conducted to:

- inform the Organization of the level of WHO's operational response to an emergency and the need for mobilization of internal and external resources;
- activate WHO's incident management system (IMS) and emergency SOPs;
- determine the need for a surge of additional human and material resources;
- permit the use of resources from the CFE above US\$ 50 000;
- convey to partners, donors and other stakeholders WHO's assessment of the scale of unmet needs within the health sector and, by extension, the requirement for additional international resources.

## Triggers for consideration of grading

The following criteria trigger the grading process:

- any public health event with a risk assessed as high or very high;
- any public health event where the RRA indicates a likely need for an operational response by WHO;
- any request for emergency assistance from a Member State.

## Timing of grading

For acute events, the grading exercise should be conducted within 24 hours of an RRA that characterizes the event as high or very high risk and indicates the likely need for an operational response by WHO. For slower-onset events due, for example, to conflict or drought, grading may happen several days after initial assessment and where applicable, use information from the PHSA to support decision-making.

## Responsibility for grading

Grading can be initiated by any level of the Organization; however, the primary responsibility lies with the RED. Representation at the grading call should include the HWCO/WR, the RED and senior representation from headquarters on behalf of the Executive Director. The grade of an emergency must be agreed across the three levels.

## WHO levels for graded emergencies

Table 1. Definitions of graded emergencies

Grade	Description
 Ungraded	The operational response does not exceed the usual country-level cooperation of the country office with the Member State. The event continues to be monitored as required.
 Grade 1	An event requiring a limited response by WHO, which exceeds the usual country-level cooperation that the country office has with the Member State. Organizational or external support required by the country office is minimal. The provision of support to the country office is coordinated by an incident manager counterpart in the regional office.
 Grade 2	An event requiring a moderate response by WHO. The level of response required by WHO always exceeds the capacity of the country office. Organizational or external support required by the country office is moderate. The provision of support to the country office is coordinated by an incident manager in the regional office. An incident manager counterpart is also appointed at headquarters to assist with the coordination of Organization-wide support as required.
 Grade 3	An event requiring a major to maximal WHO response. Organizational and external support required by the country office entails the mobilization of Organization-wide assets. The provision of support to the country office is coordinated by an incident manager at regional office level. An incident manager is also appointed at headquarters to assist with the coordination of Organization-wide technical and operational support. The Executive Director of WHE and any involved regional directors may agree to coordinate the event from headquarters. For events or emergencies involving multiple regions, an incident manager at headquarters will coordinate the response across the regions. System-wide scale up by the IASC automatically results in the declaration of a WHO Grade 3 emergency, if not already activated.



## Featured Analysis

### Emerging Technology and Risk Analysis: Synthetic Pandemics

*Report*

Rand Feb 15, 2024

Daniel M. Gerstein, Bianca Espinosa, Erin N. Leidy

Throughout history, pandemics have been a risk to human existence. Experts have warned with increasing frequency about the risk of naturally occurring pandemics, yet the emergence of the virus that causes coronavirus disease 2019 (COVID-19) brought a renewed global attention to the threats associated with pandemics. Experts now warn that humans are at increasing risk for more naturally occurring global pandemics, largely due to a wide variety of human activities. Advances in biotechnology and humans' growing capacity to program the essence of life extends to the deliberate use of biotechnology to develop biological weapons (BW), including a pathogen that could be used to cause a synthetic pandemic.

In considering the potential for a synthetic pandemic, researchers assessed whether a pathogen could be developed applying engineering principles to biology that would be capable of sustained, human-to-human transmission and causing mortality and morbidity. And, if so, how would such an engineered pandemic compare with a naturally occurring spillover event? Specifically, the authors determined that either (1) the deliberate release of an engineered pathogen by a state or bioterrorist as a weapon or (2) an inadvertent release of an engineered pathogen from a research laboratory could result in a synthetic pandemic; for this assessment, in keeping with the sponsor's interest, their primary focus was on a bioterrorist attack scenario.

The researchers considered technology availability, as well as risks and scenarios (threats, vulnerabilities, and consequences), in the next three years, three to five years, and five to ten years.

#### ***Key Findings***

- Biotechnology will continue to become more readily available, more capable, easier to use, and less expensive and require a smaller footprint.
- Increasing availability of technological capability and knowledge would increase the potential for a successful bioterrorist attack. Countries — especially those with large pharmaceutical and biotechnology sectors — would experience few impediments to developing BWs. Larger, more-capable terrorist groups would see advantages that could lead to development of large-scale bioterrorism weapon capabilities. Smaller, less skilled groups would likely still be challenged.
- Ribonucleic acid (RNA) viruses represent the likeliest of the viral agents to cause a future pandemic. RNA viruses are likeliest to infect new host species because of their shorter generation times and faster evolutionary rates.
- Although engineering a synthetic pathogen to create a pandemic will become easier, engineering the desired pathogen characteristics while maintaining competence in viral replication would still be difficult.
- The fact that a pathogen has been modified does not mean that it will be more effective than a naturally occurring virus in causing a pandemic.
- The uncertainties surrounding the transmissibility and virulence of a synthetic pandemic pathogen make the risks of synthetic and naturally occurring pandemics similar, except in the initial release of a synthetic pathogen during which victims in the initial BW release plume would likely experience overwhelming doses, which could result in reduced incubation times, greater severity of the disease, and higher mortality and morbidity rates.



## WHO - [Strategic Advisory Group of Experts on Immunization \(SAGE\) - March 2024](#)

11 – 14 March 2024 Geneva

### [Draft agenda](#)

- Global and regional reports – Session 1
- IA2030 deep dive – Session 2
- Polio – Session 3
- Hepatitis E – Session 4
- COVID-19 – Session 5
- Mpox – Session 6
- Immune correlates – Session 7
- RSV – Session 8



## Position Paper

### [Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future](#)

IFPMA *Position paper* 8 Feb 2024

PDF: [https://www.ifpma.org/wp-content/uploads/2024/02/20231201\\_IFPMA-position-paper-on-regulatory-agilities-for-vaccines-1.pdf](https://www.ifpma.org/wp-content/uploads/2024/02/20231201_IFPMA-position-paper-on-regulatory-agilities-for-vaccines-1.pdf)


This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.

### ***Conclusion, key learnings, & recommendations***

#### *Conclusion*

To support the accelerated development, evaluation, authorization, and supply of vaccines to address the COVID-19 pandemic, NRAs successfully adopted a variety of regulatory agilities. All stakeholders have an opportunity to reflect on the lessons learnt from this recent experience which can help to enhance regulatory systems, in both non-emergency and emergency contexts. The stakeholder community should continue to engage in dialogues to establish a shared way forward to enhance regulatory frameworks and support innovation and timely patient access to vaccines. Multi-stakeholder workshops, including members of NRAs, industry representatives, and potentially members of key organizations such as ICMRA, ICDRA and WHO, can allow participants to share experiences and challenges related to the use of key agilities, such as those related to PACs and labelling, and facilitate alignment on recommendations for their future adoption. Adopting agilities in regulatory decision-making can facilitate timely development, evaluation, supply, and access to safe and quality-assured vaccines at all times. The adoption of regulatory agilities in non-emergency times may also increase overall stakeholders' confidence with using agilities. This, and having established emergency frameworks, can contribute to enhancing preparedness for the next pandemic, reducing uncertainty, avoiding impasses, and ensuring that all stakeholders are able to act promptly to address the emergency and facilitate accelerated access to much-needed vaccines.

## Key learnings & recommendations



## Polio – PHEIC

### [Polio this week as of 14 Feb 2024 - GPEI](#)

#### ***Headlines***

:: A [new investment case](#) finds that successful polio transition in the 8 priority countries of the WHO Eastern Mediterranean Region will deliver a return of nearly US\$39 for every dollar spent. The study...projects economic and social benefits totaling an estimated US\$ 289.2 billion through sustaining polio assets and integrating them into expanded immunization, surveillance and emergency response programmes. These findings underscore the opportunity for national governments, donors and stakeholders to use polio assets to sustain a polio-free world and build strong, equitable and resilient health systems.

#### ***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Algeria: one circulating vaccine-derived poliovirus type 2 (cVDPV2)-positive environmental sample
- Egypt: one cVDPV2-positive environmental sample
- Niger: one cVDPV2-positive environmental sample

- Nigeria: four cVDPV2 cases and two cVDPV2-positive environmental samples
- Sudan: two cVDPV2-positive environmental samples



***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*



**WHO & Regional Offices** [to 17 Feb 2024]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

15 February 2024 Departmental news

**[WHO Launches Biomanufacturing Workforce Training Initiative to Strengthen Global Health Resilience](#)**

... WHO is launching the [Biomanufacturing Workforce Training Initiative](#). This initiative is coordinated by the [Local Production and Assistance \(LPA\) Unit](#), on behalf of the Access to Medicines and Health Products (MHP) Division at WHO, in close collaboration with the WHO Academy and WHO Science Division.

WHO [Biomanufacturing Workforce Training Initiative](#) aims to enhance bioproduction capabilities in LMICs by providing accessible and tailored training programs, aligned with WHO and international standards, and adapted to the evolving needs of the bioproduction sector...

15 February 2024 Departmental news

**[Updated WHO guidance for controlling vector-borne diseases through indoor residual spraying](#)**

13 February 2024 Departmental news

**[Strengthening the world's defenses against epidemics and pandemics: Expanding GISRS](#)**

13 February 2024 Departmental news

**[WHO launches data visualization dashboard on antimicrobial resistance and use](#)**

13 February 2024 Departmental news

**[WHO announces forthcoming updates on tuberculosis preventive treatment](#)**

12 February 2024 Departmental news

**[India gets "PRET" for future pandemics: a national consultation on developing the content framework for the National Pandemic Preparedness Plan for Respiratory Viruses](#)**



**WHO Regional Offices**

*Selected Press Releases, Announcements*

**[WHO African Region](#)**

*No new digest content identified.*

### **WHO Region of the Americas PAHO**

:: 15 Feb 2024

#### **[PAHO partners with St Jude Children's Research Hospital to improve access to medicines for childhood cancer in Latin America and the Caribbean](#)**

Washington D.C. 15 February 2024 – The Pan American Health Organization (PAHO) has announced a new partnership agreement with St. Jude Children's Research Hospital to help strengthen equitable access to cancer medications for children in Latin America and the Caribbean. The four-year agreement will focus on the provision of quality medicines...

### **WHO South-East Asia Region SEARO**

*No new digest content identified.*

### **WHO European Region EURO**

*No new digest content identified.*

### **WHO Eastern Mediterranean Region EMRO**

#### **[Sustaining polio investments offers a high return](#)**

14 February 2024 – A new investment case shows that successful polio transition in the 8 priority countries of the WHO Eastern Mediterranean Region will have a very high return on investment.

### **WHO Western Pacific Region**

*No new digest content identified.*

:::::

### **WHO - Emergency situation reports**

#### **[Multi-country outbreak of cholera, External situation report #11 - 12 February 2024](#)**

:::::

### **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

#### **[16 February 2024 | Middle East Respiratory Syndrome Coronavirus - Kingdom of Saudi Arabia](#)**

#### **[13 February 2024 | Avian Influenza A\(H10N5\) and Influenza A\(H3N2\) coinfection - China](#)**

:::::

### **Weekly Epidemiological Record**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

**Vol. 99, No. 07, pp. 69–82 16 February 2024**

<https://iris.who.int/bitstream/handle/10665/376028/WER9907-eng-fre.pdf>

:: 36th meeting of the International Task Force for Disease Eradication, 5–6 October 2023

:::::

## **New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

14 February 2024

**[The Platinum Decade: Accelerating health for billions: WHO South-East Asia Region 2014–2023](#)**

13 February 2024

**[Operational manual on indoor residual spraying: Control of vectors of malaria, Aedes-borne diseases,...](#)**

13 February 2024

**[Tuberculosis preventive treatment: rapid communication](#)**

12 February 2024

**[Independent review of the Working for health programme and its multi-partner trust fund: 2017-2022](#)**

12 February 2024

**[Emergency response framework \(ERF\), Edition 2.1](#)**

12 February 2024

**[Report of the third meeting of the Technical Advisory Group on NCD-related Research and Innovation](#)**

.....  
.....

## **USA – HHS, FDA, CDC**

### **HHS**

*News*

*No new digest content identified.*

### **FDA**

*Press Announcements*

*No new digest content identified.*

### **FDA VRBPAC**

*Advisory Committee Calendar*

**[Vaccines and Related Biological Products Advisory Committee March 5, 2024 Meeting Announcement](#)** - 03/05/2024

### **CDC/ACIP [U.S.]** [to 17 Feb 2024]

<http://www.cdc.gov/media/index.html>

*Latest News Releases*

### **[CDC Opens New East Asia and Pacific Regional Office in Japan](#)**

February 5, 2024 TOKYO, February 5, 2024 – U.S. Centers for Disease Control and Prevention (CDC) Director Mandy Cohen celebrated the opening of the new CDC East Asia and Pacific (EAP) regional office in Tokyo, Japan, at a ceremony that included U.S.

## **ACIP Meetings**

*Next ACIP Meeting*

**February 28-29**

- [Draft Agenda](#)
- [Webcast Link](#)

## **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2023.html>

**February 15, 2024 / No. 6**

[PDF of this issue](#)

- [Hepatitis A Exposure Response and Outbreak Prevention in a Large Urban Jail — Los Angeles County, California, May–July 2023](#)
- [Notes from the Field: Long COVID Prevalence Among Adults — United States, 2022](#)

.....  
.....

## **Europe**

### **European Medicines Agency [EMA]**

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

#### [Launch of new HMA-EMA catalogues of real-world data sources and studies](#)

EMA and the Heads of Medicines Agencies (HMA) have launched two public electronic catalogues: one for real-world data (RWD) sources and one for WD studies.

15 February 2024

.....

### **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

#### [High vaccination coverage key against expected increase of measles cases in the EU/EEA](#)

News story - 16 Feb 2024

#### [Increase of hypervirulent carbapenem-resistant \*Klebsiella pneumoniae\* in the EU/EEA](#)

News story - 14 Feb 2024

*Scientific and technical publications*

#### [Threat assessment brief: Measles on the rise in the EU/EEA - Considerations for public health response](#)

Risk assessment - 16 Feb 2024

.....  
.....

### **Africa CDC [to 17 Feb 2024]**

<http://www.africacdc.org/>

*Press Releases, Statements [Selected]*

#### [Africa CDC Deploys 500 Community-Based Volunteers to Support Cholera Response in Zambia](#)

12 February 2024

*Press Releases*

**[Strengthening Partnerships to Combat Disease Outbreaks in the Democratic Republic of Congo \(DRC\)](#)**

10 February 2024

*Press Releases*

**[Enhancing Vaccine Storage Efficiencies in Africa](#)**

8 February 2024, The Africa Centres for Disease Control and Prevention (Africa CDC), in collaboration with the Mastercard Foundation under the Saving Lives and Livelihoods initiative, has provided state-of-the-art cold chain equipment to five (5) African Union Member States. These Member States are Botswana, Cameroon, Sierra Leone, Uganda and Zambia, are part of the initial delivery targeting a total of 32 Member States in the phase one investment for the procurement of Cold Chain Equipment (CCE). The equipment was procured and delivered through the support of UNICEF, one of the initiative's implementing partners. The support aligns with the Africa CDC goal of strengthening healthcare systems and enhancing the response to vaccine-preventable diseases...

.....  
.....

**China CDC**

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 17 Feb 2024]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

**National Medical Products Administration – PRC** [to 17 Feb 2024]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

**China CDC**

**[Weekly Reports: Current Volume \(6\)](#)**

**[2024-02-16 / No. 7 MPOX ISSUE](#)**

[View PDF of this issue](#)

- [Preplanned Studies: Knowledge, Attitude, and Practice Towards Mpox and Associated Factors Among HIV-Infected Individuals — Beijing Municipality, China, 2023](#)
- [Review: The Current State and Progress of Mpox Vaccine Research](#)
- [Outbreak Reports: A Case of Acute HIV-1 and Monkeypox Coinfection After Condomless Insertive Anal Sex in the Previous 69 Days — Beijing Municipality, China, August–October, 2023](#)

.....  
.....

***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

## **Organization Announcements**

**Paul G. Allen Frontiers Group** [to 17 Feb 2024]

<https://alleninstitute.org/news-press/>  
*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 17 Feb 2024]

<https://www.gatesfoundation.org/ideas/media-center>  
*Press Releases and Statements*

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 17 Feb 2024]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

### **[MAM01 Demonstrates Protection Against Plasmodium falciparum \(Pf\) Malaria in Humanized Mouse Model](#)**

February 14, 2024 Publication

*Background*

Prophylactic monoclonal antibodies (mAb) targeting the circumsporozoite protein (CSP) on the surface of sporozoites (infectious stage of parasite) have been shown to be protective against *Plasmodium falciparum* (Pf) infection in humans<sup>1</sup>. The Fah<sup>-/-</sup>, Rag2<sup>-/-</sup>, Il2rγ<sup>-/-</sup> (FRG) mouse has proven to be a reliable model in which to test mAbs aimed at preventing Pf transmission via mosquito bite<sup>2</sup>. MAM01 is a mAb which targets CSP and is being developed for prevention of Pf infection in children aged 3 months to 5 years as a long-acting single dose prevention drug.

**CARB-X** [to 17 Feb 2024]

<https://carb-x.org/>

*News*

02.13.2024 |

### **[CARB-X funds the Myers Research Group to develop enhanced oral antibiotics to treat a range of serious drug-resistant bacterial infections](#)**

CARB-X is awarding US\$1.2 million to the Andrew G Myers Research Group at the Harvard University Department of Chemistry and Chemical Biology to develop a series of enhanced oral antibiotics that directly target a range of antibiotic-resistant bacteria which cause serious lower respiratory tract and skin and soft tissue infections.

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 17 Feb 2024]

<http://cepi.net/>

*Latest News*

**[Testing the tests: Scientists seek out best on-the-spot diagnostics for deadly Nipah and Lassa](#)**

In a four-year project funded by CEPI and led by FIND, the team will examine and evaluate all available point-of-care testing options for N

News

15 Feb 2024

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 17 Feb 2024]

<https://cioms.ch/>

*News; Publications; Events*

**[CIOMS Glossary of ICH terms and definitions: Version 5 now available](#)**

Version 5 of the CIOMS Glossary of ICH terms and definitions is now freely available [here](#). It can also be accessed from the ICH webpage [here](#).

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 17 Feb 2024]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 17 Feb 2024]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [to 17 Feb 2024]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

*No new digest content identified.*

**Emory Vaccine Center** [to 17 Feb 2024]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 17 Feb 2024]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Evidence Aid** [to 17 Feb 2024]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*Resources [Selected]*

**Communication to promote physical distancing for COVID-19**

Added February 16, 2024

**Testing strategies for Hepatitis B and Hepatitis C**

Added February 15, 2024

**Fondation Merieux** [to 17 Feb 2024]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 17 Feb 2024]

<https://www.gavi.org/>

*News Releases*

*No new digest content identified.*

**GE2P2 Global Foundation** [to 17 Feb 2024]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – February 2024](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 14 February 2024 – Issue 13](#)

**GHIT Fund** [to 17 Feb 2024]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 17 Feb 2024].

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 17 Feb 2024]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 17 Feb 2024]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 17 Feb 2024]

<https://www.hhmi.org/news>

*Press Room*

**[HHMI Opens National Competition for Freeman Hrabowski Scholars Program](#)**

February 14, 2024

**Human Immunome Project [nee Human Vaccines Project]** [to 17 Feb 2024]

<http://www.humanvaccinesproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 17 Feb 2024]

<https://www.iavi.org/>

*News, Features*

*No new digest content identified.*

**INSERM** [to 17 Feb 2024]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use** [to 17 Feb 2024]

<https://www.ich.org/page/press-releases>

*News/Pubs/Press Releases [Selective]*

12 February 2024

**[ICH E2D\(R1\) draft Guideline reaches Step 2 of the ICH process](#)**

The ICH E2D(R1) draft Guideline on “Post-Approval Safety Data: Definitions and Standards for Management and Reporting of individual Case Safety Reports” has reached Step 2 of the ICH process on 5 February 2024.

**ICRC** [to 17 Feb 2024]

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

## **ICRC remains extremely concerned about the lives and welfare of hostages in Gaza**

\* Hostage-taking is strictly prohibited under international humanitarian law.

14-02-2024 | Statement

## **Gaza: Increased armed hostilities in Rafah pose disastrous risk to civilian lives and infrastructure**

"In view of a military operation in densely populated Rafah, we renew our call on the parties to the conflict, and all who have influence on them, to spare and protect civilian lives and infrastructure," said Fabrizio Carboni, the ICRC's regional director.

14-02-2024 | News release

### **IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

### **IFRC** [to 17 Feb 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

*Press release 16/02/2024*

## **Ukraine: Two years on, IFRC warns of increasing debt creating unstable futures for millions**

### **Institut Pasteur** [to 17 Feb 2024]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

### **ISC / International Science Council** [to 17 Feb 2024]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

*Blogs*

## **Achieving sustainable development requires the full inclusion of women and girls in science**

Despite advancements in women's education, a significant gender gap persists across all levels of science, technology, engineering, and mathematics (STEM) globally. In recognition of this issue, on the occasion of the International Day of Women and Girls in Science, the International Science Council (ISC) supported a statement at the 9th Assembly of the International Day of Women and Girls in Science.

12.02.2024

### **International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

*No new digest content identified.*

**IVAC** [to 17 Feb 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 17 Feb 2024]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 17 Feb 2024]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

February 12:

[Johns Hopkins Center for Health Security launches new practice-oriented playbook for addressing health misinformation](#)

**MSF/Médecins Sans Frontières** [to 17 Feb 2024]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Conflict in Sudan*

[Addressing myriad medical needs amidst conflict in Sudan](#)

Voices from the Field 15 Feb 2024

*Gaza-Israel war*

[Displaced people forced to evacuate Nasser hospital have nowhere to go in Gaza](#)

Press Release 14 Feb 2024

*Gaza-Israel war*

[Ground offensive on Rafah would be catastrophic and must not proceed](#)

Statement 12 Feb 2024

**National Academy of Medicine** - USA [to 17 Feb 2024]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academy of Sciences** - USA [to 17 Feb 2024]

<https://www.nationalacademies.org/newsroom?>

*News*

*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS [to 17 Feb 2024]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

**National Vaccine Advisory Committee (NVAC) Meeting  
February 22-23, 2024 (Virtual): Agenda**

**NIH** [to 17 Feb 2024]

<http://www.nih.gov/>

*News Releases*

Wednesday, February 14, 2024

**[COVID-19 vaccination and boosting during pregnancy protects infants for six months](#)**

*What*

Women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with strong protection against symptomatic COVID-19 infection for at least six months after birth, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. These findings, published in Pediatrics(link is external), reinforce the importance of receiving both a COVID-19 vaccine and booster during pregnancy to ensure that infants are born with robust protection that lasts until they are old enough to be vaccinated...

**PATH** [to 17 Feb 2024]

<https://www.path.org/media-center/>

*Newsroom*

**[Uganda's first-ever veterinary laboratories receive recommendation for international accreditation](#)**

February 9, 2024 by PATH

**[PATH and the Conrad N. Hilton Foundation partner to promote child development services in facilities and communities](#)**

February 8, 2024 by PATH

**Sabin Vaccine Institute** [to 17 Feb 2024]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 17 Feb 2024]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

*Feature story*

**[Countries take practical steps forward towards eliminating discrimination](#)**

09 February 2024

Countries from across the world who have taken practical steps forward towards eliminating discrimination are showing what is possible, UNAIDS has said.

The countries are members of the Global Partnership for Action to Eliminate all Forms of HIV-Related Stigma and Discrimination, which have prioritized and pledged to accelerate the removal of stigmatizing and discriminatory practices, policies and laws across six settings: community, health, justice, education, workplace, and emergency/humanitarian.

**UNICEF** [to 17 Feb 2024]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*Press release 14 February 2024*

**[1.4 billion children globally missing out on basic social protection, according to latest data](#)**

NEW YORK, 14 February 2024 – Globally, 1.4 billion children aged 0-15 lack any form of social protection, leaving them vulnerable to disease, poor nutrition and poverty, according to new data released today by the International Labour Organization (ILO), Save the Children and UNICEF. In low-income countries, less than one in ten children in this...

*Press release 11 February 2024*

**[68,000 children affected by Nepal earthquake still need urgent assistance - UNICEF](#)**

KATHMANDU, Nepal, 11 February 2024 – 100 days after a 6.4 magnitude earthquake struck western Nepal on 3 November 2023, UNICEF is calling for continued support for 68,000 children and their families in the affected areas and appealing for US\$14.7 million in funding to help rebuild the lives of the affected children.

**Unitaid** [to 17 Feb 2024]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [to 17 Feb 2024]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 17 Feb 2024]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*No new digest content identified.*

**Vaccine Confidence Project** [to 17 Feb 2024]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 17 Feb 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 17 Feb 2024]

<https://wellcome.org/>

*News, Opinion, Reports*  
*No new digest content identified.*

**The Wistar Institute** [to 17 Feb 2024]  
<https://www.wistar.org/news/press-releases>

*Press Releases*  
February 14, 2024

**[The Wistar Institute Announces New Caspar Wistar Fellow, Dr. Irene Bertolini](#)**

Wistar scientist joins faculty to pursue research in breast and brain cancers  
PHILADELPHIA—(Feb. 13, 2024)— The Wistar Institute, an international biomedical research leader in cancer, infectious disease, immunology, and vaccine development...

**World Bank** [to 015 Oct 2022]  
<http://www.worldbank.org/en/news/all>

*All News [Selected]*  
*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 17 Feb 2024]  
<https://www.wfpha.org/>

*Blog*  
*No new digest content identified.*

**[World Medical Association \[WMA\]](#)** [to 17 Feb 2024]  
<https://www.wma.net/news-press/press-releases/>

*Press Releases*  
**[WMA Takes Stand Against Humanitarian Violations, Calls for Urgent Action in Gaza](#)**  
16 Feb 2024

In response to the ongoing conflict in Gaza, the World Medical Association (WMA) reiterates its call for medical neutrality and strongly condemns any violations of international humanitarian laws and demands the safety of all civilians, especially children, as well as healthcare personnel and facilities...

**World Organisation for Animal Health** [to 17 Feb 2024]  
<https://www.oie.int/en/>

*Press Releases, Statements*  
*No new digest content identified.*

.....

**ARM [Alliance for Regenerative Medicine]** [to 17 Feb 2024]  
<https://alliancerm.org/press-releases/>

*Selected Press Releases*  
*No new digest content identified.*

**BIO** [to 17 Feb 2024]  
<https://www.bio.org/press-releases>

*Press Releases*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 17 Feb 2024]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 17 Feb 2024]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

**IFPMA** [to 17 Feb 2024]

<https://ifpma.org/>

*Position paper* 8 Feb 2024

**[Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future](#)**

This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.

**International Alliance of Patients' Organizations – IAPO** [to 17 Feb 2024]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

**[Call to Heads of State of the African Union to Ratify and Operationalise the African Medicines Agency Treaty](#)**

Wednesday, 14 February 2024

The members of the [African Medicines Agency Treaty Alliance \(AMATA\)](#), an alliance representing African patients, academia, civil society, and industry, urge Member States as they convene for the 37th African Union (AU) Summit (17th – 18th February 2024) to expedite the unanimous ratification and operationalisation of the African Medicines Agency (AMA) Treaty to ensure timely access to quality medicines that are safe and effective for all patients in Africa...

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest announcements identified.*

**PhRMA** [to 17 Feb 2024]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

.....

.....

## ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

### **AstraZeneca**

Press Releases - No new digest announcements identified.

### **Bharat Biotech**

Press Releases - No new digest announcements identified.

### **BioCubaFarma – Cuba**

Últimas Noticias - No new digest announcements identified

### **Biological E**

News - No new digest announcements identified

### **BioNTech**

Press Releases

12 February 2024

[\*\*BioNTech Receives Science Based Targets Initiative Validation for Near-term Emissions Reduction Targets\*\*](#)

### **Boehringer**

Press Releases - No new digest announcements identified.

### **CanSinoBIO**

News - Website not responding at inquiry

### **CIGB**

Latest News - No new digest announcements identified.

### **Cinnagen**

Recent News - No new digest announcements identified.

### **Clover Biopharmaceuticals - China**

News - No new digest announcements identified.

### **Curevac [Bayer Ag – Germany]**

News - No new digest announcements identified

### **Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

### **GSK**

Press releases for media

Press releases

15 February 2024

[\*\*GSK completes acquisition of Aiolos Bio\*\*](#)

12 February 2024

[\*\*GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B\*\*](#)

**IMBCAMS, China**

Home - Website not responding at inquiry.

**Janssen/JNJ**

Press Releases - No new digest announcements identified

**Merck**

News releases - No new digest announcements identified

**Moderna**

Press Releases - No new digest announcements identified

**Nanogen**

News - No new digest announcements identified

**Novartis**

News - No new digest announcements identified.

**Novavax**

Press Releases - No new digest announcements identified.

**Pfizer**

Recent Press Releases - No new digest announcements identified

**R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

**Sanofi Pasteur**

Press Releases - No new digest announcements identified

**Serum Institute of India**

NEWS & ANNOUNCEMENTS - No new digest announcements identified

**Sinopharm/WIBPBIBP**

News - No new digest announcements identified [English translation function not operating]

**Sinovac**

Press Releases - No new digest announcements identified

**SK Biosciences**

Press Releases - No new digest announcements identified.

**Takeda**

Newsroom - No new digest announcements identified

**Valneva**

Press Releases - No new digest announcements identified.

**Vector State Research Centre of Virology and Biotechnology**

Home - Website not responding [404 error]

## **WestVac Biopharma**

*Media* - No new digest announcements identified.

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

*Website* [No News/Announcements page identified]



### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)



### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 15, 2023 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 26, Number 2: E97-194 Feb 2024

<https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education>

#### ***Health Ecology and Disease Transmission***

About 75% of emerging infectious diseases are now zoonotic, with continued climate change expected to exacerbate transmission in environments shared among plants, human animals, and domestic, agricultural, and wild nonhuman animals. One Health is an approach that promotes national and international collaboration and coordinated responses to human population growth, agricultural encroachment and deforestation, ecosystem disruption, and interactions that intensify human-nonhuman animal transmission risks. Climate change diminishes biodiversity; diminished biodiversity undermines natural ecological balance dynamics between pathogens and hosts and has already influenced health care dramatically. This theme issue investigates the nature and scope of our collective responses to key changes.

[Reviewed earlier]

**American Journal of Human Genetics**

Feb 01, 2024 Volume 111 Issue 2p211-402

<https://www.cell.com/ajhg/current>

**[This Month in The Journal](#)**

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Human genetic variation influences susceptibility to infectious disease. Antibodies, stable biological markers of the response to infection, can be measured and leveraged to understand disease exposure, chronic infection state, and risk. Measured antibody titers in combination with genome-wide genotyping data can be used to identify common variants that influence both susceptibility and response to infectious disease. In this issue, Chong et al. perform a genome-wide association study of quantitative antibody responses to 45 antigens on the 9,611 individuals in the UK Biobank with both serology and imputed genetic data.

**American Journal of Infection Control**

February 2024 Volume 52 Issue 2 p141-260

<http://www.ajicjournal.org/current>

[New issue; No digest content identified]

**American Journal of Preventive Medicine**

February 2024 Volume 66 Issue 2 p195-388

<https://www.ajpmonline.org/current>

[New issue; No digest content identified]

**American Journal of Public Health**

February 2024 114(2)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

**American Journal of Tropical Medicine and Hygiene**

Volume 110 (2024): Issue 2 (Feb 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/2/tpmd.110.issue-2.xml>

[New issue; No digest content identified]

**Annals of Internal Medicine**

January 2024 Volume 177, Issue 1

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 327 February 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/327/suppl/C>

[Reviewed earlier]

## **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 17 Feb 2024)

[No new digest content identified]

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 17 Feb 2024)

[No new digest content identified]

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 17 Feb 2024)

### **[Six dilemmas for stakeholders inherently affecting data sharing during a zoonotic \(re-\)emerging infectious disease outbreak response](#)**

*Timely access to outbreak related data, particularly in the early events of a spillover, is important to support evidence based control measures in response to outbreaks of zoonotic Emerging Infectious Disease...*

Authors: Martine Y. van Roode, Carolina dos S. Ribeiro, Elmoubasher Farag, Mohamed Nour, Aya Moustafa, Minahil Ahmed, George Haringhuizen, Marion P.G. Koopmans and Linda H.M. van de Burgwal

Citation: BMC Infectious Diseases 2024 24:185

Content type: Research Published on: 12 February 2024

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmethics/content>

(Accessed 17 Feb 2024)

[No new digest content identified]

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmmed/content>

(Accessed 17 Feb 2024)

[No new digest content identified]

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 17 Feb 2024)

[No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 17 Feb 2024)

### **[Perceptions and beliefs of community gatekeepers about genomic risk information in African cleft research](#)**

*A fundamental ethical issue in African genomics research is how socio-cultural factors impact perspectives, acceptance, and utility of genomic information, especially in stigmatizing conditions like orofacial ...*

Authors: Abimbola M. Oladayo, Oluwakemi Odukoya, Veronica Sule, Ikenna Molobe, Tamara Busch, Babatunde Akodu, Wasiu L. Adeyemo, Lord J. J. Gowans, Mekonen Eshete, Azeez Alade, Waheed Awotoye, Adebowale A. Adeyemo, Peter A. Mossey, Anya E. R. Prince, Jeffrey C. Murray and Azeez Butali

Citation: BMC Public Health 2024 24:507

Content type: Research Published on: 17 February 2024

**[Heterogeneity in COVID-19 vaccine uptake within low-income minority communities: evidence from the watts neighborhood health study](#)**

*The literature on disparities in COVID-19 vaccine uptake focuses primarily on the differences between White versus non-White individuals or differences by socioeconomic status. Much less is known about dispari...*

Authors: Elizabeth Wong, Ying Liu, Victoria Shier and Ashlesha Datar

Citation: BMC Public Health 2024 24:503

Content type: Research Published on: 16 February 2024

**BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 17 Feb 2024)

[No new digest content identified]

**BMJ Evidence-Based Medicine**

February 2024 - Volume 29 - 1

<https://ebm.bmj.com/content/29/1>

[Reviewed earlier]

**BMJ Global Health**

February 2024 - Volume 9 - 2

<https://gh.bmj.com/content/9/2>

[Reviewed earlier]

**Bulletin of the Atomic Scientists**

January 2024

<https://thebulletin.org/magazine/2024-01/>

[Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 102(2); 2024 Feb 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/454958/>

[Reviewed earlier]

**Cell**

Feb 15, 2024 Volume 187 Issue 4 p797-1016

<https://www.cell.com/cell/current>

*Featured Article*

### **[Live-attenuated chikungunya virus vaccine](#)**

Lisa F.P. Ng, Laurent Rénia

Although Chikungunya fever does not have a high fatality rate (<10%), it has a huge morbidity toll due to lingering chronic arthralgia. The recent FDA approval of Ixchiq, a vaccine designed to prevent infection caused by the chikungunya virus (CHIKV), provides hope that its use can prevent future CHIKV outbreaks.

### **Child Care, Health and Development**

Volume 50, Issue 2 March 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[New issue; No digest content identified]

### **Clinical Pharmacology & Therapeutics**

Volume 115, Issue 3 Pages: 375-626 March 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

### ***Subcutaneous Biologics: Clinical Pharmacology and Drug Development***

*Perspectives Open Access*

### **[Current Perspectives on Data Sharing and Open Science in Pharmacogenomics](#)**

Deanne Nixie R. Miao, Feryal Ladha, Sarah M. Lyle, Daniel W. Olivier, Samah Ahmed, Britt I. Drögemöller

Pages: 408-411

First Published: 13 December 2023

Genome-wide association studies (GWAS) summary statistics provide opportunities to accelerate human genomics research. In pharmacogenomics, assembling large, statistically powerful sample sizes is challenging, emphasizing the vital role of data sharing. To investigate data sharing practices in this field, we reviewed the availability of GWAS summary statistics in 593 pharmacogenomic GWAS articles and found that only 2% contained links to publicly available summary statistics. This highlights the need for improved data sharing initiatives within the pharmacogenomics community.

### **Clinical Therapeutics**

January 2024 Volume 46 Issue 1 p1-84

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

### **Clinical Trials**

Volume 21 Issue 1, February 2024

<https://journals.sagepub.com/toc/ctja/21/1>

[New issue; No digest content identified]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 17 Feb 2024]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 137 February 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/137/suppl/C>

[New issue; No digest content identified]

### **The CRISPR Journal**

Volume 6, Issue 6 / December 2023

<https://www.liebertpub.com/toc/crispr/6/6>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 40, Issue 2 2024

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

February 2024 - Volume 37 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

### **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 17 Feb 2024]

[No new digest content identified]

### **Developing World Bioethics**

Volume 23, Issue 4 Pages: 293-377 December 2023

<https://onlinelibrary.wiley.com/toc/14718847/current>

*ORIGINAL ARTICLES*

[Reviewed earlier]

### **Development in Practice**

Volume 34, Issue 1, 2024

<http://www.tandfonline.com/toc/cdip20/current>

[New issue; No digest content identified]

### **Development Policy Review**

Volume 42, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

## **Disaster Medicine and Public Health Preparedness**

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

## **Disasters**

Volume 48, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/1>

[Reviewed earlier]

## **EMBO Reports**

Volume 25 Issue 2 13 February 2024

<https://www.embopress.org/toc/14693178/current>

*Opinion* 23 January 2024

### **[The ineligibility barrier for international researchers in US academia](#)**

Mikael H Elias, Kitty Sompiyachoke [...] Shina Caroline Lynn Kamerlin

Many grants from US funding agencies are restricted to US citizens or permanent residents which negatively impacts the career options for foreign scientists working in the USA.

*Science & Society* 2 January 2024

### **[Re-defining the human embryo](#)**

Iñigo De Miguel Beriain, Jon Rueda, Adrian Villalba

A universal legal definition of an embryo as a basis for regulation would create legal certainty for scientists and benefit international research cooperation.

## **Emerging Infectious Diseases**

Volume 30, Number 2—February 2024

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

## **Epidemics**

Volume 45 December 2023

<https://www.sciencedirect.com/journal/epidemics/vol/45/suppl/C>

[Reviewed earlier]

## **Epidemiology and Infection**

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

## **Ethics & Human Research**

Volume 46, Issue 1 Pages: 1-48 January–February 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

**• Local context and emergency research • Participant fraud in online research  
Passing demands in autism research :: Women missing in phase I trials**

[Reviewed earlier]

**Ethics & International Affairs**

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

**Ethics, Medicine and Public Health**

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

**The European Journal of Public Health**

Volume 33, Issue 6, December 2023

<https://academic.oup.com/eurpub/issue/33/6>

[Reviewed earlier]

**Expert Review of Vaccines**

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

**Foreign Affairs**

January/February 2024 Volume 103, Number 1

<https://www.foreignaffairs.com/issues/2023/103/1>

[Reviewed earlier]

**Forum for Development Studies**

Volume 51, 2023 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

[New issue; No digest content identified]

**Genetics in Medicines**

Volume 26, Issue 2 February 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/2>

[New issue; No digest content identified]

**Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 17 Feb 2024]

[No new digest content identified]

## **Global Health Action**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

Vol. 11, No. 6 December 22, 2023

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

## **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 17 Feb 2024]

[No new digest content identified]

## **Global Public Health**

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

## **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 17 Feb 2024]

[No new digest content identified]

## **Health and Human Rights**

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

***Special Section: Economic Inequality and the Right to Health***

[Reviewed earlier]

## **Health Economics, Policy and Law**

Volume 19 - Issue 1 - January 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>  
*Article*

**[Early child health in Africa: do ICT and democracy matter?](#)**

Gaston Brice Nkoumou Ngoa, Jacques Simon Song

Published online by Cambridge University Press:

06 November 2023, pp. 92-118

*Abstract*

This article examines the effect of information and communication technologies (ICT) and democracy on early child health using data from 51 African countries. We first specify and estimate a panel data model using ordinary least squares and two-stage least squares over the period 2001–

2019. We apply the Hodrick–Prescott filter before analysis. Our results show that the extension of mobile phone use significantly contributes to the improvement of early child health in Africa. This effect is indifferent to the state or the level of democracy. Also, the internet diffusion plays a positive role in early child health when the democracy environment improves and becomes better. We suggest policies in favour of a large access to ICT tools and internet infrastructure as well as the promotion of democracy in Africa to better prevent infant mortality.

### **Health Policy and Planning**

Volume 38, Issue 10, December 2023

<https://academic.oup.com/heapol/issue/38/10>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 17 Feb 2024]

*Research Open access*

Published: 14 February 2024

#### **[Future directions for patient engagement in research: a participatory workshop with Canadian patient partners and academic researchers](#)**

Anna Maria Chudyk, Roger Stoddard, Todd A. Duhamel, Patient Engagement in Research Partners & Annette S. H. Schultz

*Abstract*

*Background*

Patient engagement in research (also commonly referred to as patient or patient and public involvement in research) strives to transform health research wherein patients (including caregivers and the public) are regularly and actively engaged as multidisciplinary research team members (i.e. patient partners) working jointly towards improved health outcomes and an enhanced healthcare system. To support its mindful evolution into a staple of health research, this participatory study aimed to identify future directions for Canadian patient engagement in research and discusses its findings in the context of the international literature.

### **Human Gene Therapy**

Volume 35, Issue 1-2 / January 2024

<https://www.liebertpub.com/toc/hum/35/1-2>

[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

## **Immunity**

Feb 13, 2024 Volume 57 Issue 2 p193-400

<https://www.cell.com/immunity/current>

[New issue; No digest content identified]

## **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 17 Feb 2024]

[No new digest content identified]

## **Infectious Diseases of Poverty**

<http://www.idpjournal.com/content>

[Accessed 17 Feb 2024]

[No new digest content identified]

## **International Health**

Volume 15, Issue 6, November 2023

<https://academic.oup.com/inthealth/issue/15/6>

[Reviewed earlier]

## **International Human Rights Law Review**

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml>

*Table of Contents*

[Reviewed earlier]

## **International Journal of Community Medicine and Public Health**

Vol. 11 No. 1 (2024): January 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/108>

[Reviewed earlier]

## **International Journal of Epidemiology**

Volume 52, Issue 6, December 2023

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

## **International Journal of Human Rights in Healthcare**

Volume 16 Issue 5 2023

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/5>

*Table of contents*

[Reviewed earlier]

## **JAMA**

February 13, 2024, Vol 331, No. 6, Pages 457-538  
<https://jamanetwork.com/journals/jama/currentissue>  
[New issue; No digest content identified]

### **JAMA Health Forum**

February 2024, Vol 5, No. 2  
<https://jamanetwork.com/journals/jama-health-forum/issue>  
[Reviewed earlier]

### **JAMA Pediatrics**

February 2024, Vol 178, No. 2, Pages 104-208  
<https://jamanetwork.com/journals/jamapediatrics/currentissue>  
[Reviewed earlier]

### **JBIC Evidence Synthesis**

January 2024 - Volume 22 - Issue 1  
<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>  
[Reviewed earlier]

### **Journal of Adolescent Health**

March 2024 Volume 74 Issue 3 p395-628  
<https://www.jahonline.org/current>  
[Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 79 (2024)  
<https://www.jair.org/index.php/jair>  
*Contents*  
[Reviewed earlier]

### **Journal of Community Health**

Volume 48, issue 6, December 2023  
<https://link.springer.com/journal/10900/volumes-and-issues/48-6>  
[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*  
Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996  
<https://www.cmro.in/index.php/jcmro/issue/view/75>  
[New issue; No digest content identified]

### **Journal of Development Economics**

Volume 166 January 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/166/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 18 Issue 5, December 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

February 2024 - Volume 78 - 2

<https://jech.bmj.com/content/78/2>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 16, Issue 4 Pages: 415-580 December 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[New issue; No digest content identified]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 34, Number 4, November 2023

<https://muse.jhu.edu/issue/51329>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 25, issue 6, December 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-6>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 22, 2024 \_ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 228, Issue 12, 15 December 2023

<https://academic.oup.com/jid/issue/228/12>

[Reviewed earlier]

**Journal of International Development**

Volume 36, Issue 1 Pages: 1-772 January 2024  
<https://onlinelibrary.wiley.com/toc/10991328/current>  
[Reviewed earlier]

**Journal of Medical Ethics**

February 2024 - Volume 50 - 2  
<http://jme.bmj.com/content/current>  
[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 10, Issue 4 (2023)  
<https://institutionalrepository.aah.org/jpcrr/>  
[Reviewed earlier]

**The Journal of Pediatrics**

Volume 264 January 2024  
<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/264/suppl/C>  
[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024) Issue 1  
<https://www.tandfonline.com/toc/jppp20/17/1>  
[Reviewed earlier]

**Journal of Public Health Management & Practice**

January/February 2024 - Volume 30 - Issue 1  
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>  
[Reviewed earlier]

**Journal of Public Health Policy**

Volume 44, issue 4, December 2023  
<https://link.springer.com/journal/41271/volumes-and-issues/44-4>  
[Reviewed earlier]

**Journal of the Royal Society – Interface**

February 2024 Volume 21 Issue 211  
<https://royalsocietypublishing.org/toc/rsif/current>  
[Reviewed earlier]

**Journal of Travel Medicine**

Volume 31, Issue 1, January 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

### **Journal of Virology**

Volume 97 • Number 12 • December 2023

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

Feb 17, 2024 Volume 403 Number 10427 p587-698

<https://www.thelancet.com/journals/lancet/issue/current>

*Seminar*

#### **Dengue**

Gabriela Paz-Bailey, Laura E Adams, Jacqueline Deen, Kathryn B Anderson, Leah C Katzelnick

*Summary*

Dengue, caused by four closely related viruses, is a growing global public health concern, with outbreaks capable of overwhelming health-care systems and disrupting economies. Dengue is endemic in more than 100 countries across tropical and subtropical regions worldwide, and the expanding range of the mosquito vector, affected in part by climate change, increases risk in new areas such as Spain, Portugal, and the southern USA, while emerging evidence points to silent epidemics in Africa. Substantial advances in our understanding of the virus, immune responses, and disease progression have been made within the past decade. Novel interventions have emerged, including partially effective vaccines and innovative mosquito control strategies, although a reliable immune correlate of protection remains a challenge for the assessment of vaccines. These developments mark the beginning of a new era in dengue prevention and control, offering promise in addressing this pressing global health issue.

### **The Lancet Child & Adolescent Health**

Mar 2024 Volume 8 Number 3 p175-244, e2-e5

<https://www.thelancet.com/journals/lanchi/issue/current>

*Editorial*

#### **A vote for childhood NTD elimination**

The Lancet Child & Adolescent Health

At least 1·2 billion children and adolescents (<25 years)—one in six globally—are affected by one or more neglected tropical diseases (NTDs). As a group of common infections with relatively cheap treatments, NTDs are precipitated by extreme poverty and perpetuated through political neglect. For children there are added challenges in avoiding infection and accessing safe medicines. NTD elimination efforts have withstood years of tumultuous global dynamics marked by escalating conflict and climate disasters, and local actors have overcome seemingly insurmountable challenges. Yet, with root causes in some of the most divisive election topics—poverty, inequality, marginalisation, and climate—NTD partners and programmes could emerge jeopardised or strengthened in 2024, as people in at least 60 countries go to the polls...

Even in worst-case scenarios for 2024, NTD elimination efforts only stand to benefit from a child-centred and equity-focused dismantling of the systemic obstacles to treating and eliminating NTDs. In this vein, a growing body of evidence shows the potential of health-promoting schools to bring together children in a clean and safe environment where they can receive deworming, vaccines, and health checks in tandem with health literacy education and nutritious meals. A key research priority is advancing coverage beyond schools to reach those who are too young or poor for school. The

future is uncertain, but advocacy, collaboration, and resource mobilisation will ensure childhood NTD partners and programmes triumph.

### *Review*

#### **[Incorporating parental values in complex paediatric and perinatal decisions](#)**

Prof Dominic J C Wilkinson, MBBS DPhil

### *Summary*

Incorporating parental values in complex medical decisions for young children is important but challenging. In this Review, we explore what it means to incorporate parental values in complex paediatric and perinatal decisions. We provide a narrative overview of the paediatric, ethics, and medical decision-making literature, focusing on value-based and ethically complex decisions for children who are too young to express their own preferences. We explain key concepts and definitions, discuss paediatric-specific features, reflect on challenges in learning and expressing values for both parents and health-care providers, and provide recommendations for clinical practice. Decisional values are informed by global and external values and could relate to the child, the parents, and the whole family. These values should inform preferences and assure value-congruent choices. Additionally, parents might hold various meta values on the process of decision making itself. Complex decisions for young children are emotionally taxing, ethically difficult, and often surrounded by uncertainty. These contextual factors make it more likely that values and preferences are initially absent or unstable and need to be constructed or stabilised. Health-care professionals and parents should work together to construct and clarify values and incorporate them into personalised decisions for the child. An open communication style, with unbiased and tailored information in a supportive environment, is helpful. Dedicated training in communication and shared decision making could help to improve the incorporation of parental values in complex decisions for young children.

### **Lancet Digital Health**

Feb 2024 Volume 6 Number 2 e87-e144

<https://www.thelancet.com/journals/landig/issue/current>

[New issue; No digest content identified]

### **Lancet Global Health**

Mar 2024 Volume 12 Number 3 e341-e529

<https://www.thelancet.com/journals/langlo/issue/current>

### *Editorial*

#### **[The landscape for rare diseases in 2024](#)**

### *Articles*

#### **[Estimating the subnational prevalence of antimicrobial resistant Salmonella enterica serovars Typhi and Paratyphi A infections in 75 endemic countries, 1990–2019: a modelling study](#)**

GRAM Typhoid Collaborators

#### **[Long-term immunity following yellow fever vaccination: a systematic review and meta-analysis](#)**

Jenny L Schnyder, Hanna K de Jong, Bache E Bache, Frieder Schaumburg, Martin P Grobusch

#### **[Cost-effectiveness of intervention combinations towards the elimination of vertical transmission of HIV in limited-resource settings: a mathematical modelling study](#)**

Joshua M Chevalier, et al.

[Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania \(DoRIS\) with one dose in young women aged 15–20 years in Kenya \(KEN SHE\): an immunobridging analysis of randomised controlled trials](#)

Kathy Baisley, et al.

*Viewpoint*

[Beyond tuberculosis: a person-centred and rights-based approach to screening for household contacts](#)

Claire J Calderwood, et al.

[Antimicrobial resistance and the great divide: inequity in priorities and agendas between the Global North and the Global South threatens global mitigation of antimicrobial resistance](#)

Marc Mendelson, et al.

**Lancet Infectious Diseases**

Feb 2024 Volume 24 Number 2 p107-216, e70-e136

<https://www.thelancet.com/journals/laninf/issue/current>

*Editorial*

[A new dawn for malaria prevention](#)

The Lancet Infectious Diseases

*[Excerpt]*

...The availability of R21/Matrix-M should complement RTS,S/AS01 and guarantee vaccination is available for all those in need at the global level. Children eligible for R21/Matrix-M are between 5 months and 3 years old. About 80 million eligible children live in malaria-endemic regions of sub-Saharan Africa. 240 million doses are needed to give them all three doses of the vaccines in 2024, followed by a further 80 million boosters in 2025. After that, including currently unvaccinated children, the roughly 30 million children born every year would need 120 million doses. This would save about 450 000 lives a year.

Now the deployment of both vaccines in the field opens new questions: should a booster be given each year to children until they reach school age? How easily can malaria vaccination be added to the complex immunisation schedule already in place for children in malaria-endemic countries? In the current landscape of highly localised malaria transmission, with spots of high and low malaria prevalence found in the same country, as seen in Tanzania or Kenya, will vaccination remain cost-effective? Still, it seems the day when all children at risk of malaria can be offered a vaccine has arrived, and we cherish the work of all those who have paved the way to this historical achievement.

*Articles*

[Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial](#)

Mary-Claire R Walsh, et al.

[Boostability after single-visit pre-exposure prophylaxis with rabies vaccine: a randomised controlled non-inferiority trial](#)

Lisanne A Overduin, et al.

*Personal View*

[Boosting pathogen genomics and bioinformatics workforce in Africa](#)

Harris Onywera, et al.

*Grand Round*

[\*\*Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications\*\*](#)

Carmela Pinnetti, et al.

### **Lancet Public Health**

Feb 2024 Volume 9 Number 2 e68-e146

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

### **Lancet Respiratory Medicine**

Feb 2024 Volume 12 Number 2 p89-180, e1-e6

<https://www.thelancet.com/journals/lanres/issue/current>

[New issue; No digest content identified]

### **Maternal and Child Health Journal**

Volume 27, issue 12, December 2023

<https://link.springer.com/journal/10995/volumes-and-issues/27-12>

[Reviewed earlier]

### **Medical Decision Making (MDM)**

Volume 44 Issue 2, February 2024

<http://mdm.sagepub.com/content/current>

*Restricted access Research article* First published January 13, 2024pp. 163–174

[\*\*Perceptions of COVID-19 Risk: How Did People Adapt to the Novel Risk?\*\*](#)

Karen Sepucha, et al.

*Open Access Research article* First published December 30, 2023pp. 175–188

[\*\*Bias-Adjusted Predictions of County-Level Vaccination Coverage from the COVID-19 Trends and Impact Survey\*\*](#)

Marissa B. Reitsma, et al.

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 101, Issue 4 Pages: 999-1374 December 2023

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

### **Molecular Therapy**

Feb 07, 2024 Volume 32 Issue 2 p261-562

<https://www.cell.com/molecular-therapy/current>

*Editorials*

[\*\*A new frontier: FDA approvals for gene therapy in sickle cell disease\*\*](#)

Alexis Leonard, John F. Tisdale

On December 8, 2023, the US Food and Drug Administration (FDA) approved two autologous gene therapy products, Lyfgenia (lovotibeglogene autotemcel by bluebird bio) and Casgevy (exagamglogene autotemcel by Vertex Pharmaceuticals), for the treatment of individuals with sickle cell disease (SCD) ages 12 years and older with recurrent vaso-occlusive events (VOEs).<sup>1</sup> Lyfgenia utilizes a lentiviral vector (LVV)-based strategy to transduce autologous hematopoietic stem cells (HSCs) with a LVV encoding  $\beta$ A-T87Q, an anti-sickling globin.

## **Nature**

Volume 626 Issue 7999, 15 February 2024

<https://www.nature.com/nature/volumes/625/issues/7999>

*Perspective* 14 Feb 2024

### **[Optimally generate policy-based evidence before scaling](#)**

To reduce voltage drops—the depreciation of the cost–benefit profile when scaling up solutions to social problems—sufficient policy-based evidence must be generated before policymakers scale up the project.

John A. List

## **Nature Biotechnology**

Volume 42 Issue 2, February 2024

<https://www.nature.com/nbt/volumes/42/issues/2>

*Editorial* 15 Feb 2024

### **[Spotlight on protein structure design](#)**

New methods for protein design speed up workflows, but issues of training data availability and method optimization remain.

*Patents* 15 Feb 2024

### **[Contracts and intellectual property rights in translational R&D: furthering safeguards in the public interest](#)**

Intellectual property safeguards should be more widely incorporated into the bilateral contracts that underpin the translational R&D process to preserve the public interest, especially where public funds and resources have spearheaded the innovation process.

Mark Anderson, Naomi Hawkins, Alison Slade

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 17 Feb 2024)

[No new digest content identified]

## **Nature Genetics**

Volume 56 Issue 2, February 2024

<https://www.nature.com/ng/volumes/56/issues/2>

*Comment* 08 Feb 2024

### **[Advancing diagnosis and research for rare genetic diseases in Indigenous peoples](#)**

Achieving a diagnosis for Indigenous people living with a rare, often genetic, disease is crucial for equitable healthcare. The International Rare Disease Research Consortium convened a global Task Force to bridge the gap in diagnosing Indigenous rare diseases, and identify solutions to tackle the health inequity faced by Indigenous people.

Gareth Baynam, Daria Julkowska, Barend Christiaan Vorster

## **Nature Human Behaviour**

Volume 8 Issue 1, January 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/1>

[Reviewed earlier]

## **Nature Medicine**

Volume 30 Issue 1, January 2024

<https://www.nature.com/nm/volumes/30/issues/1>

[Reviewed earlier]

## **Nature Reviews Drug Discovery**

Volume 23 Issue 2, February 2024

<https://www.nature.com/nrd/volumes/23/issues/2>

*Comment* 09 Jan 2024

### **[Disproportional inflation of clinical trial costs: why we should care, and what we should do about it](#)**

Clinical trial costs seem to be inflating excessively, without a clear increase in the value of the information gained. Here, we highlight factors that could be driving this trend and discuss potential solutions.

Hemme J. Hijma, Ahnjili Zhuparris, Adam F. Cohen

*Review Article* 04 Dec 2023

### **[tRNA therapeutics for genetic diseases](#)**

The potential of harnessing tRNAs to treat genetic diseases has recently gained significant attention. Here, Coller and Ignatova provide an overview of the history and potential applications of tRNA-based therapies, summarize advances in tRNA cargo design and delivery strategies, and assess the challenges encountered in establishing tRNAs as effective and safe therapeutics.

Jeff Coller, Zoya Ignatova

## **Nature Reviews Genetics**

Volume 25 Issue 2, February 2024

<https://www.nature.com/nrg/volumes/25/issues/2>

*Review Article* 25 Sep 2023

### **[Genomic surveillance for antimicrobial resistance — a One Health perspective](#)**

Antimicrobial resistance (AMR) is an important public health issue that affects human, animal and environmental sectors worldwide. The authors review the role of genomics in AMR surveillance using a One Health approach, and how genomic approaches can help mitigate the spread of AMR to improve global health.

Steven P. Djordjevic, Veronica M. Jarocki, Benjamin P. Howden

## **Nature Reviews Immunology**

Volume 24 Issue 2, February 2024

<https://www.nature.com/nri/volumes/24/issues/2>

*Comment* 11 Jan 2024

### **[Integrated organ immunity: a path to a universal vaccine](#)**

Considering immune responses through the framework of 'integrated organ immunity' could enable the design of a new class of universal vaccines.

Bali Pulendran

*Comment* 18 Jan 2024

### **Using BCG vaccination to protect against COVID-19: when reality fails to meet expectation**

While anticipating the development of a COVID-19-specific vaccine several randomized controlled trials (RCTs) explored the potential of BCG vaccination to protect against COVID-19, based on trials demonstrating beneficial effects of BCG vaccination on unrelated infections and all-cause mortality in neonates in high-mortality geographical settings. Results are now available from 12 RCTs, which suggest that BCG vaccination is not an effective intervention against COVID-19. That the BCG–COVID-19 trials failed to meet expectation emphasizes the importance of rigorous clinical trials to validate hypotheses, even in urgent situations such as a pandemic.

Laure F. Pittet, Christie C. A. Noble, Nigel Curtis

### **New England Journal of Medicine**

February 15, 2024 Vol. 390 No. 7

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

### **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 17 Feb 2024]

[No new digest content identified]

### **Pediatrics**

Volume 153, Issue 2 February 2024

<https://publications.aap.org/pediatrics/issue/153/2>

[Reviewed earlier]

### **PharmacoEconomics**

Volume 42, Issue 2 February 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-2>

[Reviewed earlier]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 17 Feb 2024)

[No new digest content identified]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 17 Feb 2024)

[No new digest content identified]

## **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 17 Feb 2024)

### **[Improved vaccination coverage after two rounds of multi-antigenic catch-up vaccination in Mauritania](#)**

Maider Pagola-Ugarte, Ankur Rakesh, Julita Gil-Cuesta, David Kidinda, Thierno Moctar Kelly, Sidi Zahaf, Mohamed Mahmoud O. Ely Mahmoud, Mohamedou O. Mohamed Salem, Mbareck Houmeid, Dah Cheikh, Naceredine Ouldzeidoune, Catherine Bachy

Research Article | published 14 Feb 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002939>

### **[Barriers and facilitators to utilizing HIV prevention and treatment services among migrant youth globally: A scoping review](#)**

Kevin Li, Natasha Thaweesee, Allison Kimmel, Emily Dorward, Anita Dam

Research Article | published 14 Feb 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002851>

## **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 17 Feb 2024)

[No new digest content identified]

## **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 17 Feb 2024)

[No new digest content identified]

## **PLoS One**

<http://www.plosone.org/>

[Accessed 17 Feb 2024]

### **[How can we promote vaccination of the mass population?—Lessons from the COVID-19 vaccination defaults](#)**

Masaki Takebayashi, Mira Namba, Yudai Kaneda, Tatsuya Koyama, Soichiro Miyashita, Kurenai Takebayashi, Motoki Ohnishi

Research Article | published 16 Feb 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0298983>

## **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 17 Feb 2024]

[No new digest content identified]

## **PNAS - Proceedings of the National Academy of Sciences of the United States**

February 13, 2024 vol. 121 no. 7

<https://www.pnas.org/toc/pnas/121/7>

*Research Article* February 6, 2024

### **[Design of universal Ebola virus vaccine candidates via immunofocusing](#)**

The Ebola virus causes hemorrhagic fever in humans and poses a significant threat to global public health. Although two viral vector vaccines have been approved to prevent Ebola virus disease, they are distributed in the limited ring vaccination setting ...

Duo Xu, Abigail E. Powell, [...] Peter S. Kim

### **PNAS Nexus**

Volume 3, Issue 1, January 2024

<https://academic.oup.com/pnasnexus/issue/3/1>

[Reviewed earlier]

### **Prehospital & Disaster Medicine**

Volume 38 - Issue 6 - December 2023

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

### **Preventive Medicine**

Volume 178 January 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/178/suppl/C>

[Reviewed earlier]

### **Proceedings of the Royal Society B**

14 February 2024 Volume 291 Issue 2016

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

### **Public Health**

Volume 226 Pages e1-e6, 1-274 (January 2024)

<https://www.sciencedirect.com/journal/public-health/vol/226/suppl/C>

[Reviewed earlier]

### **Public Health Ethics**

Volume 16, Issue 3, November 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

### **Public Health Genomics**

2023, Vol. 26, No. 1

<https://karger.com/phg/issue/26/1>

[Reviewed earlier]

### **Public Health Reports**

Volume 139 Issue 1, January/February 2024

<https://journals.sagepub.com/toc/phrg/139/1>

[Reviewed earlier]

### **Qualitative Health Research**

Volume 34 Issue 3, February 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

### **Research Ethics**

Volume 20 Issue 1, January 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 17 Feb 2024]

[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

12 Feb 2024

[Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension](#)

Special report | Spanish |

### **Risk Analysis**

Volume 44, Issue 2 Pages: 281-507 February 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 17 Feb 2024]

[Reviewed earlier]

### **Science**

Volume 383| Issue 6684| 16 Feb 2024

<https://www.science.org/toc/science/current>

*Editorial*

[Science communication at scale](#)

BY H. Holden Thorp 15 Feb 2024

### **Science and Engineering Ethics**

Volume 30, Issue 1 February 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-1>

[Reviewed earlier]

### **Science Translational Medicine**

Volume 16| Issue 734| 14 Feb 2024

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 17 Feb 2024]

[No new digest content identified]

### **Social Science & Medicine**

Volume 340 January 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/340/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 17 Feb 2024]

#### **[The global economic burden of COVID-19 disease: a comprehensive systematic review and meta-analysis](#)**

The COVID-19 pandemic has caused a considerable threat to the economics of patients, health systems, and society.

Authors: Ahmad Faramarzi, Soheila Norouzi, Hossein Dehdarirad, Siamak Aghlmand, Hasan Yusefzadeh and Javad Javan-Noughabi

Citation: Systematic Reviews 2024 13:68

Content type: Systematic review update Published on: 16 February 2024

### **Theoretical Medicine and Bioethics**

Volume 44, Issue 6 December 2023

<https://link.springer.com/journal/11017/volumes-and-issues/44-6>

[Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 57 January–February 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/57/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 29, Issue 1 Pages: i-iv, 1-71 January 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

## **Vaccine**

Volume 42, Issue 4 Pages 723-994 (6 February 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/4>

[Reviewed earlier]

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 17 Feb 2024]

*Latest Articles [Selected]*

*[No new digest content identified]*

## **Value in Health**

February 2024 Volume 27 Issue 2 p133-270

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

## **World Development**

Volume 175 March 2024

<https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C>

[Reviewed earlier]



### ***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*



### ***Pre-Print Servers***

## **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 17 Feb 2024]

*Selected Research*

[No new digest content identified]

## **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 17 Feb 2024]

*[Filter: All articles]*

[No new digest content identified]

### **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences]

Registration

#### **[Key elements of health research systems for pandemic prevention, preparedness, and response: a scoping review](#)**

Sassy Molyneux , Alice Norton , and Nicolas Pulik

Date registered: 2024-02-15 Date modified: 2024-02-15

Since the COVID-19 pandemic, literature on health system resilience and improvements has flourished. However, this has not been the case for literature focusing specifically on health research systems. Therefore, this scoping review aims to identify the key components of health research systems in preparedness and response situations. It will also identify tools used to assess the effectiveness and the efficiency of health research systems.

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 17 Feb 2024]

Selected Research

Research Article Open Access

#### **["Kuteteza": A community-engaged COVID-19 Prevention and Protection Initiative in Southern Malawi](#)**

[version 1; peer review: awaiting peer review]

Donnie Mategula \* for the Kuteteza study group

Abstract

Background

The COVID-19 epidemic in Malawi involved almost 90,000 recorded cases and 2,638 deaths. Data suggest that the Malawi epidemic developed largely in urban settings, but the extent of rural spread – exposing older adults in particular – is unclear. This concern led us, to develop the 'Kuteteza' partnership project: a community-based Public Health intervention involving the shielding of older adults and additional strategies to mitigate COVID-19 impacts in rural Malawi. We now present the results of a realist project evaluation...

\* \* \* \*

### **[Think Tanks](#)**

**Brookings** [to 17 Feb 2024]

<http://www.brookings.edu/>

Research

No new digest content identified.

**Center for Global Development** [to 17 Feb 2024]

<https://www.cgdev.org/>

All Research [Selected]

No new digest content identified.

**Chatham House** [to 17 Feb 2024]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [to 17 Feb 2024]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 17 Feb 2024]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

**Kaiser Family Foundation** [to 17 Feb 2024]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

**[Few Nursing Facility Residents and Staff Have Gotten the Latest COVID-19 Vaccines](#)**

February 13, 2024 News Release

Fewer nursing facility residents and staff are getting COVID-19 vaccines, according to a [new KFF analysis](#) of federal data. Only 38% of residents and 15% of staff have received the latest vaccine. In comparison, 50% of residents and 22% of staff received updated vaccines in 2022 and 87% of residents and 88% of staff completed the initial vaccination series...

**McKinsey Global Institute** [to 17 Feb 2024]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 17 Feb 2024]

<https://odi.org/en/publications/>

*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 17 Feb 2024]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*News*

*No new digest content identified.*

**Rand** [to 17 Feb 2024]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*Report*

### **Emerging Technology and Risk Analysis: Synthetic Pandemics**

Researchers provide an assessment of the risk of a nefarious actor developing a synthetic pandemic using an engineered virus. They considered technology availability, threat, vulnerability, and consequences.

Feb 15, 2024

Daniel M. Gerstein, Bianca Espinosa, Erin N. Leidy

**Urban Institute** [to 17 Feb 2024]

<https://www.urban.org/publications>

### **New Research Publications - Selected**

*Research Report*

### **Do No Harm Guide: Crafting Equitable Data Narratives**

February 16, 2024

...This sixth guide of the Urban Institute's *Do No Harm* project explores the concept of crafting equitable data narratives. What does equity mean? Who does equity include? What methods do we use to ensure equity in data work? How do we present the data in a way that show the humanity they represent?...

**World Economic Forum** [to 17 Feb 2024]

<https://agenda.weforum.org/press/>

*Media [Selected]*

No new digest content identified.

.....  
.....

## **Public Consultations/Call for Inputs/Call for Papers**

### **Call for Papers: Establishing the impact of WHO's normative and standard-setting functions: a call for papers**

WHO - Bull World Health Organ. 2023 Oct 1; 101(10): 618–618A. Published online 2023 Oct 1.

**The deadline for submissions is 1 March 2024**

*Editorial*

Lisa M Askie<sup>a</sup>, Rebekah AL Thomas<sup>a</sup>, Rok Ho Kim<sup>a</sup>, Mubashar Sheikh<sup>a</sup>, Jeremy Farrar<sup>b</sup>

doi: 10.2471/BLT.23.290829 PMID: PMC10523809

Normative leadership is a core function of the World Health Organization's (WHO) mandate, as outlined in its founding principles.<sup>1</sup> This leadership role is realized by developing evidence-based and ethically sound guidelines as well as other normative products that guide Member States in their public health decisions and actions, and by ensuring their recommendations are implemented.<sup>2</sup> WHO exercises its capacity for normative leadership to influence the development of legal norms and health policy and practice within its Member States...

... In the past five years, WHO has initiated a major change process, driven by its current Thirteenth Global Programme of Work,<sup>6</sup> the transformation agenda, and the need to respond to major global events including the coronavirus disease 2019 (COVID-19) pandemic and other crises. More recently, WHO has developed a comprehensive strategy to enhance its capacities and capabilities at country level, to ensure that its normative work drives measurable impact for all people more effectively.

Despite these initiatives, to date it is unclear whether these changes have improved WHO's credibility and impact as a normative organization. Questions remain as to how successful WHO's normative leadership role has been, how it can be further strengthened and how the impact of WHO's work in countries should be measured and rated in the future. The recent COVID-19 pandemic exposed both the strengths of and the challenges to WHO's normative leadership and global reach. While realizing the crucial role of WHO as a key directing and coordinating authority, the global health community has also witnessed the unprecedented rise of misinformation and mistrust in science.

Considering the spotlight on WHO's global normative leadership role during the pandemic,<sup>7</sup> and looking to prepare for future threats such as the health effects of climate change and ongoing conflict situations, the Bulletin of the World Health Organization calls for papers to help shape and inform WHO's mandate going forward. Topics of interest include: where has WHO succeeded in its normative leadership role? In what specific areas has it successfully shaped global health, and why were these initiatives successful? Where has WHO normative guidance been less impactful? If so, why was this the case, and what lessons can be learnt to improve impact in the future? What does the future of WHO's normative function look like, particularly in the context of digital technology and artificial intelligence? What aspects of the Organization's mandate, structure, function and administration need to be further strengthened or changed?

The Bulletin welcomes contributions from all stakeholders including public health decision-makers, researchers, and civil society and community representatives. Articles that propose innovative but feasible ways by which WHO can further strengthen its normative leadership and guidance role, are encouraged.

\* \* \* \* \*  
\* \* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \* \*  
\* \* \* \* \*